The stockholder vote on November 4 is the key catalyst; approval is required for the cash distribution and merger to proceed. The ex-dividend date on the closing date means the stock price will adjust downward by approximately the distribution amount. Monitor for any last-minute opposition or vote shortfall.
Price Chart
Executive Summary
Rallybio Corp declared an estimated $82.7 million special cash distribution ($13.56 per share) in connection with its pending merger with Avenzo Therapeutics. The distribution is conditioned on stockholder approval at the November 4, 2026 annual meeting, with closing expected on or about November 6, 2026. This filing updates the merger timeline and provides details on the cash distribution mechanics.
Key Financial Metrics
Key Facts
- Board declared a special cash distribution estimated at $82.7 million aggregate, or $13.56 per share, payable to stockholders and pre-funded warrant holders of record as of November 5, 2026.
- Distribution is conditioned on receipt of the Required Company Stockholder Vote at the annual meeting scheduled for November 4, 2026.
- Closing of the merger with Avenzo Therapeutics is expected on or about November 6, 2026.
- Estimated per share distribution based on 6,378,168 shares of common stock and common stock equivalents outstanding as of October 21, 2026.
- Cash Distribution per share exceeds 25% of the stock price on declaration date, triggering an ex-dividend date of the closing date (expected November 6, 2026).
- Due bill period expected from November 4, 2026 through November 6, 2026.
- Board also fixed the record date for distribution of contingent value rights in connection with the merger.
Financial Impact
Estimated $82.7 million cash distribution ($13.56 per share) to stockholders, representing a substantial portion of the company's net cash. The company's market cap is $87M, so the distribution is roughly 95% of market cap.
Risk Factors
- Failure to obtain Required Company Stockholder Vote at the November 4 meeting would prevent the cash distribution and merger from closing.
- The actual cash distribution amount may differ from the $82.7 million estimate based on final net cash calculation per the merger agreement.
- Any legal proceedings or regulatory delays could push back the expected closing timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-432123 |
| Document: 0001193125-26-432123-index-headers.html | 0001193125-26-432123 |
| Document: 0001193125-26-432123-index.html | 0001193125-26-432123 |
| Document: 0001193125-26-432123.txt | 0001193125-26-432123 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $16.40 | awaiting T+60 | — | $15.93 (−2.87%) |
Oct 26, 2026 1d ago | 8-K | $16.65 | awaiting T+60 | — | $15.93 (−4.32%) |
Oct 16, 2026 11d ago | EFFECT | $16.28 | awaiting T+60 | — | $15.93 (−2.15%) |
Oct 14, 2026 13d ago | S-4/A | $16.78 | awaiting T+60 | — | $15.93 (−5.04%) |
Jul 15, 2026 14w ago | S-4 | $15.96 $17.02 | ▲ +6.64% | ▲ +2.93% | $15.93 (−0.19%) |
Jun 1, 2026 21w ago | 425 | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.93 (−5.57%) |
Jun 1, 2026 21w ago | 8-K | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.93 (−5.57%) |
May 4, 2026 25w ago | 8-K | $14.12 $15.96 | ▲ +13.03% | ▲ +11.17% | $15.93 (+12.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers